|
|
|
26.03.26 - 23:48
|
XFRA: DIVIDEND/INTEREST INFORMATION - 30.03.2026 - JP3160400002 (XETRA)
|
|
|
Das Instrument EII JP3160400002 EISAI CO. LTD EQUITY wird cum Dividende/Zinsen gehandelt am 27.03.2026 und ex Dividende/Zinsen am 30.03.2026
The instrument EII JP3160400002 EISAI CO. LTD EQUITY has its pre-dividend/interest day on 27.03.2026 and its ex-dividend/interest day on 30.03.2026...
|
|
|
|
|
|
|
25.03.26 - 04:54
|
Research Team Confirms Safety of Alzheimer′s Drug Lecanemab (Nippon)
|
|
|
Tokyo, March 25 (Jiji Press)--More than 90 pct of patients receiving Lecanemab, an Alzheimer's drug, in hospitals across Japan have been able to continue treatment without strong side effects, a group of researchers in the country said. Lecanemab, developed by Eisai Co. and Biogen Inc. and put on sale in December 2023, removes amyloid beta from the brain to slow the progress of Alzheimer's ......
|
|
|
24.03.26 - 12:06
|
Newron Presents 2025 Financial Results and Provides 2026 Outlook (Business Wire)
|
|
|
Ad hoc announcement pursuant to Art. 53 LRMILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--$NWRN #schizophrenia--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2025, and provided an outlook for 2026.
Highlights 2025:
Evenamide
Initiation of pivotal Phase III ENIGMA-TRS clinical program
In May, the Company announced regulatory approval for its pivotal Phase III ENIGMA-TRS program with evenamide as an add-on therapy in patients with treatment-resistant schizophrenia (TRS). The program comprises two pivotal studies, ENIGMA-TRS 1 and ENIGMA-TRS 2.
Post-period, in January 2026, Newron's partner EA Pharma (Eisai Group), who has the rights to develop, manufacture and commercialize evenamide in Japan and other designated Asian territories, initiat...
|
|
|
|
|
|
|
|
|
20.03.26 - 10:48
|
England to Review Rejection of Alzheimer′s Drugs for NHS (Bloomberg)
|
|
|
England's drug price regulator will reconsider its decision to rule out using Eli Lilly & Co.'s Alzheimer's disease treatment — and another made Eisai Co. and Biogen Inc. — in the state-run National Health Service, following successful appeals by the companies....
|
|
|
11.03.26 - 13:03
|
Cognito Therapeutics Appoints Thomas Fagan as Executive Vice President, Alzheimer′s Portfolio (Business Wire)
|
|
|
Former Eisai and Eli Lilly Alzheimer's disease leader joins executive team to advance commercialization strategy for Spectris™CAMBRIDGE, Mass.--(BUSINESS WIRE)--#alzheimers--Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive therapies for neurodegenerative diseases, today announced the appointment of Thomas Fagan as Executive Vice President, Alzheimer's Portfolio, and a member of the company's Executive Leadership Team.
Mr. Fagan brings more than 25 years of leadership experience across the pharmaceutical, medical device, and diagnostics industries, with deep expertise in Alzheimer's disease spanning diagnostics, therapeutics, and real-world clinical adoption. He has extensive experience building and aligning cross-functional teams, developing clinical-to-commercial pathways, and working with clinicians, health systems, and payers to accelerate adoption of innovative medical technologies.
In his role at Cognito, Mr. Fagan will lead the company's Alzheimer's...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18.02.26 - 18:06
|
Sift Biosciences Announces Oversubscribed $3.7M Pre-seed Financing to Advance Next-generation T-cell Immunotherapy Platform (Business Wire)
|
|
|
Pre-Seed Round Co-Led By Freeflow Ventures and Lifespan Vision Ventures With Participation From Valuence Ventures, Eisai Innovation, SBI US Gateway Fund and othersSAN CARLOS, Calif.--(BUSINESS WIRE)--#AIdriven--Sift Biosciences, a UC Berkeley spinout developing a next-generation peptide immunotherapy platform that integrates AI, metagenomics, and high-throughput immune profiling, today announced the closing of a $3.7M Pre-Seed financing, co-led by Freeflow Ventures and Lifespan Vision Ventures, with participation from Valuence Ventures, Eisai Innovation, SBI US Gateway Fund and other early supporters.
Sift is building a new class of peptide-based immunotherapies designed to engage pre-existing memory T cells to overcome the lack of immunogenicity that limits current cancer immunotherapies. The company's initial focus is on immunologically “cold” solid tumors, including microsatellite-stable colorectal and ovarian cancers, where patients have few effective treatment options.
“Most immunotherapies fa...
|
|
|
18.02.26 - 08:54
|
BioArctic Interim Report for the period October - December 2025 (PR Newswire)
|
|
|
STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- A transformative year with record financial results Events during the fourth quarter 2025 Leqembi® Iqlik™ was launched for weekly maintenance dosing and Eisai completed rolling sBLA submission for subcutaneous initiation treatment in the US Leqembi......
|
|
|
18.02.26 - 08:39
|
BioArctic Interim Report for the period October - December 2025 (PR Newswire)
|
|
|
STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- A transformative year with record financial results Events during the fourth quarter 2025 Leqembi® Iqlik™ was launched for weekly maintenance dosing and Eisai completed rolling sBLA submission for subcutaneous initiation treatment in the US Leqembi......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
